165 related articles for article (PubMed ID: 17853434)
1. The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP.
Belzunegui S; San Sebastián W; Garrido-Gil P; Izal-Azcárate A; Vázquez-Claverie M; López B; Marcilla I; Lanciego JL; Luquin MR
Synapse; 2007 Dec; 61(12):1006-12. PubMed ID: 17853434
[TBL] [Abstract][Full Text] [Related]
2. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR
Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984
[TBL] [Abstract][Full Text] [Related]
3. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
[TBL] [Abstract][Full Text] [Related]
4. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus.
Shaw VE; Keay KA; Ashkan K; Benabid AL; Mitrofanis J
Parkinsonism Relat Disord; 2010 Jun; 16(5):338-44. PubMed ID: 20227323
[TBL] [Abstract][Full Text] [Related]
6. The isolation of neural stem cells from the olfactory bulb of Parkinson's disease model.
Hayakawa H; Hayashita-Kinoh H; Nihira T; Seki T; Mizuno Y; Mochizuki H
Neurosci Res; 2007 Mar; 57(3):393-8. PubMed ID: 17222932
[TBL] [Abstract][Full Text] [Related]
7. Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?
Luquin MR; Saldise L; Guillén J; Belzunegui S; San Sebastián W; Izal A; Garrido P; Vázquez M
Exp Neurol; 2006 Oct; 201(2):407-15. PubMed ID: 16806173
[TBL] [Abstract][Full Text] [Related]
8. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
[TBL] [Abstract][Full Text] [Related]
9. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the olfactory bulb and the striatum in mice.
Mitsumoto Y; Mori A; Ohashi S; Nakai M; Moriizumi T
Neurosci Res; 2005 Jan; 51(1):111-5. PubMed ID: 15596247
[TBL] [Abstract][Full Text] [Related]
11. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not elicit long-lasting increases in cyclooxygenase-2 expression in dopaminergic neurons of monkeys.
Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Belzunegui S; Izal-Azcárate A; López B; Marcilla I; Luquin MR
J Neuropathol Exp Neurol; 2009 Jan; 68(1):26-36. PubMed ID: 19104449
[TBL] [Abstract][Full Text] [Related]
12. Gender-related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients.
Huisman E; Uylings HB; Hoogland PV
Mov Disord; 2008 Jul; 23(10):1407-13. PubMed ID: 18581481
[TBL] [Abstract][Full Text] [Related]
13. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice.
Bezard E; Dovero S; Bioulac B; Gross C
Exp Neurol; 1997 Nov; 148(1):288-92. PubMed ID: 9398471
[TBL] [Abstract][Full Text] [Related]
14. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
[TBL] [Abstract][Full Text] [Related]
15. New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis.
Tandé D; Höglinger G; Debeir T; Freundlieb N; Hirsch EC; François C
Brain; 2006 May; 129(Pt 5):1194-200. PubMed ID: 16481374
[TBL] [Abstract][Full Text] [Related]
16. Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?
Heise CE; Teo ZC; Wallace BA; Ashkan K; Benabid AL; Mitrofanis J
Anat Embryol (Berl); 2005 Nov; 210(4):287-302. PubMed ID: 16237536
[TBL] [Abstract][Full Text] [Related]
17. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease.
Huisman E; Uylings HB; Hoogland PV
Mov Disord; 2004 Jun; 19(6):687-92. PubMed ID: 15197709
[TBL] [Abstract][Full Text] [Related]
18. FGF-2 deficiency does not alter vulnerability of the dopaminergic nigrostriatal system towards MPTP intoxication in mice.
Zechel S; Jarosik J; Kiprianova I; Schober A; Unsicker K; von Bohlen und Halbach O
Eur J Neurosci; 2006 Mar; 23(6):1671-5. PubMed ID: 16553632
[TBL] [Abstract][Full Text] [Related]
19. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys.
Garrido-Gil P; Belzunegui S; San Sebastián W; Izal-Azcárate A; López B; Marcilla I; Luquin MR
J Neurosci Res; 2009 Feb; 87(2):586-97. PubMed ID: 18798285
[TBL] [Abstract][Full Text] [Related]
20. Neurogenesis in olfactory bulb identified by retroviral labeling in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated adult mice.
Yamada M; Onodera M; Mizuno Y; Mochizuki H
Neuroscience; 2004; 124(1):173-81. PubMed ID: 14960349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
